Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596617 | 0.90 | PIP4K2A (0.42) | PIP4K2AGPR119CYP2C9CYP3A4EGFR | |
| SCHEMBL12596557 | 0.89 | CYP3A4 (0.49) | PIP4K2AGPR119CYP2C9CYP3A4EGFR | |
| SCHEMBL12649155 | 0.89 | PIP4K2A (0.49) | PIP4K2AGPR119CYP2C9KCNH2CYP3A4 | |
| SCHEMBL12596599 | 0.88 | PIP4K2A (0.46) | PIP4K2AGPR119CYP2C9CYP3A4EGFR | |
| SCHEMBL12395354 | 0.88 | GPR119 (0.49) | PIP4K2AGPR119EGFR | |
| SCHEMBL12596827 | 0.88 | CYP2C9 (0.51) | GPR119CYP2C9CYP3A4EGFR | |
| SCHEMBL12596610 | 0.88 | PIP4K2A (0.44) | PIP4K2AGPR119CYP2C9KCNH2CYP3A4 | |
| SCHEMBL12596607 | 0.87 | PIP4K2A (0.44) | PIP4K2AGPR119CYP2C9CYP3A4EGFR | |
| SCHEMBL12596413 | 0.86 | GPR119 (0.55) | PIP4K2AGPR119 | |
| SCHEMBL12596559 | 0.86 | PIP4K2A (0.44) | PIP4K2AGPR119CYP2C9CYP3A4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | GPR119, GCGR, GPR35 | PIP4K2A 2352/4885GPR119 1/4885CYP2C9 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.